Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-09
-
Diclofenac for Advanced Pharmacokinetic Modeling in Intes...
2025-09-26
Explore how Diclofenac, a non-selective COX inhibitor, is revolutionizing pharmacokinetic and inflammation research using next-generation human intestinal organoid platforms. This article provides unique insights into leveraging Diclofenac for precise cyclooxygenase inhibition assays and drug metabolism studies.
-
2025-09-25
Discover how CB-5083, a selective p97 inhibitor, enables advanced exploration of ER-associated protein degradation and lipid synthesis regulation. This article uncovers unique experimental strategies and mechanistic insights, surpassing prior reviews on p97 inhibition and cancer research.
-
Anti Reverse Cap Analog (ARCA): Unveiling Post-Transcript...
2025-09-24
Explore how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, enables precise post-transcriptional control and translational enhancement in synthetic mRNA. This article uniquely integrates metabolic regulation insights and cutting-edge mRNA cap analog strategies for next-generation research.
-
Angiotensin II in AAA Research: Dissecting Senescence-Dri...
2025-09-23
Explore how Angiotensin II, a potent vasopressor and GPCR agonist, facilitates innovative vascular smooth muscle cell hypertrophy research and advances our understanding of hypertension and abdominal aortic aneurysm mechanisms.
-
Vardenafil HCl Trihydrate: Tools for Proteoform-Selective...
2025-09-22
Explore how Vardenafil HCl Trihydrate, a potent and selective phosphodiesterase type 5 inhibitor, enables advanced studies of cGMP signaling and smooth muscle relaxation. This article examines its unique value for proteoform-specific and membrane-context PDE5 inhibition assays.
-
TNF-alpha Recombinant Murine Protein: Tools for Apoptosis...
2025-09-19
Explore how TNF-alpha recombinant murine protein empowers apoptosis and inflammation research by enabling functional studies of the TNF receptor signaling pathway. This article highlights novel intersections with mitochondrial apoptotic responses, providing fresh context for cytokine-driven cell death models.
-
Annexin V-FITC/PI Apoptosis Assay Kit: Advancing Flow Cyt...
2025-09-18
Explore the applications of the Annexin V-FITC/PI Apoptosis Assay Kit in dissecting cell death mechanisms, with a focus on its significance for flow cytometry apoptosis detection and studies of chemoresistance in cancer research.
-
There are human genes in the
2025-03-03
There are 12 human genes in the SLC5A family, and 6 of these are expressed in human heart (Table 2). Little is known about SGLT proteins in the heart. Zhou et al. [56] reported the presence of SGLT1 mRNA in the human heart. Researchers have found that levels of SGLT1 mRNA in heart are approximately
-
IGF signaling has been shown to induce chromatin changes
2025-03-01
IGF-1 signaling has been shown to induce BET bromodomain inhibitor changes via interacting with MKK-p38 signaling (Serra et al., 2007) and by perturbing Foxo3a signaling (Stitt et al., 2004), among other mechanisms. The current study demonstrates that the acetyl group itself may be limiting, since I
-
The compounds containing beryllium act as strong Lewis
2025-03-01
The compounds containing beryllium act as strong Lewis acids because of electron deficiency of the Be Methoxy-X04 []. Interactions of X-Be-Y compounds with different Lewis bases have been studied by Yanez and co-workers [], extensively. Recently, they proposed a class of extremely strong bidentate
-
In conclusion we report that the widely prescribed drug
2025-03-01
In conclusion, we report that the widely prescribed drug VPA exerts therapeutic effects on optic nerve demyelination and retinal degeneration in a mouse model of MS. Our findings raise an interesting possibility that combination therapy of VPA and ASK1 inhibition may be useful for treatment of autoi
-
br Materials and methods br Results
2025-03-01
Materials and methods Results Discussion The current treatment modalities for colorectal cancer are hampered by various issues such as high acquired resistance, long-term complication with potential of cancer recurrence, severe side-effects and poor therapeutic index [50], [51], [52]. Comp
-
Cobimetinib br Conclusions br Transparency document br
2025-03-01
Conclusions Transparency document Acknowledgements This work was supported by a grant from the European Commission FP6 “Neuroprion” – Network of Excellence and Royal Veterinary College Bioveterinary science research project funding. We thank Professor Alun Williams (Cambridge University) fo
-
br Materials and methods br Results br
2025-03-01
Materials and methods Results Discussion Intracellular metabolic pathways of sugar, such as glycolysis and TCA cycle, provide material and energy for the synthesis of other substances, including amino acids. Thus, the content of sugars and their metabolic pathways are important for amino (E
-
To date LOX is the
2025-03-01
To date, 12-LOX is the only LOX isoform that has been identified in the platelet [17]. Interestingly, while 12-LOX is highly expressed (∼14000 molecules/platelet) in the platelet, 12(R)-LOX expression is absent in the hematopoietic lineage and has therefore not been reported to be expressed in plate